Segment Reporting

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

The Company evaluates performance based on the operating profit (loss) of the respective business segments. The segment results may not represent actual results that would be expected if they were independent, stand-alone businesses. Segment information is as follows:

Balance Sheet Data:	As of September 30, 2013
	Ligand			CyDex			Total
Total assets	$	38,270		$	63,407		$	101,677
	As of December 31, 2012
	Ligand			CyDex			Total
Total assets	$	28,731		$	75,529		$	104,260
Operating Data:	For the three months ended September 30, 2013
	Ligand			CyDex			Total
Net revenues from external customers	$	4,731		$	8,274		$	13,005
Depreciation and amortization expense	62			606			668
Operating (loss) income	(1,142		)	4,212			3,070
Interest expense, net	394			—			394
Income tax expense (benefit) from continuing operations	70			(10		)	60
	For the nine months ended September 30, 2013
	Ligand			CyDex			Total
Net revenues from external customers	$	14,789		$	19,448		$	34,237
Depreciation and amortization expense	179			1,828			2,007
Write-off of in-process research and development	—			480			480
Operating income	(944		)	9,462			8,518
Interest expense, net	1,755			—			1,755
Income tax expense (benefit) from continuing operations	301			(64		)	237
Gain on sale of Avinza Product Line before income taxes	2,588			—			2,588
	For the three months ended September 30, 2012
	Ligand			CyDex			Total
Net revenues from external customers	$	3,708		$	2,667		$	6,375
Depreciation and amortization expense	34			604			638
Operating (loss) income	(1,601		)	176			(1,425		)
Interest expense, net	735			—			735
Income tax expense (benefit) from continuing operations	173			(31		)	142
	For the nine months ended September 30, 2012
	Ligand			CyDex			Total
Net revenues from external customers	$	11,728		$	6,025		$	17,753
Depreciation and amortization expense	162			1,816			1,978
Operating loss	(3,560		)	(520		)	(4,080		)
Interest expense, net	2,198			—			2,198
Income tax expense (benefit) from continuing operations	543			(98		)	445
Gain on sale of Avinza Product Line before income taxes	3,656			—			3,656
Income tax benefit from discontinued operations	14			—			14